ZA201503036B - Chimeric vaccine antigens against hepatitis c virus - Google Patents

Chimeric vaccine antigens against hepatitis c virus

Info

Publication number
ZA201503036B
ZA201503036B ZA2015/03036A ZA201503036A ZA201503036B ZA 201503036 B ZA201503036 B ZA 201503036B ZA 2015/03036 A ZA2015/03036 A ZA 2015/03036A ZA 201503036 A ZA201503036 A ZA 201503036A ZA 201503036 B ZA201503036 B ZA 201503036B
Authority
ZA
South Africa
Prior art keywords
virus
vaccine antigens
against hepatitis
antigens against
chimeric vaccine
Prior art date
Application number
ZA2015/03036A
Other languages
English (en)
Inventor
Blanco Sonia Gonzalez
Donato Gillian Martínez
Ponce De León Liz Alvarez-Lajonchere
Cañizares Yalena Amador
Noriega Daylen Aguilar
Carrera Santiago Dueñas
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of ZA201503036B publication Critical patent/ZA201503036B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2015/03036A 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus ZA201503036B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
ZA201503036B true ZA201503036B (en) 2016-01-27

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/03036A ZA201503036B (en) 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus

Country Status (15)

Country Link
US (1) US9676825B2 (enExample)
EP (1) EP2915544B1 (enExample)
JP (1) JP6259831B2 (enExample)
KR (1) KR102093495B1 (enExample)
CN (1) CN104837498B (enExample)
AR (1) AR093341A1 (enExample)
AU (1) AU2013339846B2 (enExample)
CA (1) CA2901346C (enExample)
CU (1) CU24112B1 (enExample)
ES (1) ES2644801T3 (enExample)
IN (1) IN2015DN03925A (enExample)
MX (1) MX358507B (enExample)
RU (1) RU2639504C2 (enExample)
WO (1) WO2014067498A1 (enExample)
ZA (1) ZA201503036B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
WO2018055535A2 (en) * 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE
US12048742B2 (en) 2018-03-16 2024-07-30 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
EP2222336A2 (en) * 2007-10-29 2010-09-01 GENimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
US8728489B2 (en) * 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
MX358507B (es) 2018-08-22
ES2644801T3 (es) 2017-11-30
CN104837498A (zh) 2015-08-12
WO2014067498A1 (es) 2014-05-08
MX2015005651A (es) 2015-08-20
CU20120153A7 (es) 2014-06-27
RU2639504C2 (ru) 2017-12-21
AU2013339846B2 (en) 2017-08-17
US20150307558A1 (en) 2015-10-29
EP2915544B1 (en) 2017-08-09
RU2015121429A (ru) 2016-12-27
AU2013339846A1 (en) 2015-05-14
IN2015DN03925A (enExample) 2015-10-02
CA2901346C (en) 2019-04-23
JP2015536936A (ja) 2015-12-24
US9676825B2 (en) 2017-06-13
CA2901346A1 (en) 2014-05-08
JP6259831B2 (ja) 2018-01-10
AR093341A1 (es) 2015-06-03
CU24112B1 (es) 2015-08-27
CN104837498B (zh) 2018-05-18
KR102093495B1 (ko) 2020-03-26
KR20150079694A (ko) 2015-07-08
EP2915544A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
IL262123A (en) Influenza virus vaccines and their uses
IL261204A (en) Influenza virus vaccines and their use
PL2935313T3 (pl) Szczepionki przeciwko wirusowi zapalenia wątroby typu b
ZA201404797B (en) Influenza virus vaccines and uses thereof
IL235890A0 (en) vaccine
PT2806891T (pt) Vacinas baseadas no vírus parainfluenza 5
ZA201404516B (en) Vaccines against hpv
ZA201306720B (en) Hepatitis c virus inhibitors
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
IL229331A0 (en) Inhibitors for the hepatitis c virus
ZA201503458B (en) Hepatitis c virus inhibitors
SG10201702292YA (en) Novel attenuated dengue virus strains for vaccine application
ZA201503036B (en) Chimeric vaccine antigens against hepatitis c virus
IL231494A0 (en) Lentiviral genome without chimeric integration as components against hiv-1
GB201301119D0 (en) Viral vaccines
PL2850075T3 (pl) Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
SG11201507455WA (en) Hepatitis b virus vaccines
SG11201505170WA (en) Dengue virus vaccine composition
AU2013905065A0 (en) Viral vaccine
AU2013904384A0 (en) Viral vaccine
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine